Table 2.
Comparison of endocervical adenocarcinoma and endometrial adenocarcinoma immunohistochemical staining patterns.
| Endocervical Adenocarcinoma (n = 9) | Endometrial Adenocarcinoma (n = 81) | p value | |
|---|---|---|---|
| CEA | 77.8% (7/9) | 30.9% (25/81) | 0.008* |
| Vimentin | 11.1% (1/9) | 76.5% (62/81) | 0.002* |
| P16 | 77.8% (7/9) | 13.6% (11/81) | 0.001* |
| ER | 11.1% (1/9) | 92.6% (75/81) | <0.001* |
| PR | 11.1 (1/9) | 77.8% (63/81) | 0.001* |
| PAX-2 | 11.1% (1/9) | 13.6% (11/81) | 0.99 |
| PAX-8 | 66.7% (6/9) | 96.3% (78/81) | 0.013* |
| CAIX | 11.1% (1/9) | 48.2% (39/81) | 0.039* |
| Arid1a | 88.9% (8/9) | 70.4% (57/81) | 0.435 |
| PTEN | 66.7% (6/9) | 45.7% (37/81) | 0.301 |
| HNF1b | 11.1% (1/9) | 75.3% (61/81) | 0.69 |
*
Statistically significant where p value <0.05.